Pharmaceuticals is the first in Latin America to use IBM cognitive computing in skin care product research
TheraSkin, a specialized Brazilian pharmaceutical company and a reference in dermatology throughout the country, is the first company in Latin America to use the IBM Watson for Drug Discovery solution. The use of the cognitive computing platform aims to help the RD&I area in the development of products that provide the market with increasingly efficient, innovative solutions capable of meeting the wishes of the medical community and its consumers.
Watson for Drug Discovery is an IBM cloud-hosted solution that leverages cognitive computing to deliver dynamic visualizations and rankings of clinical research. This analysis is based on evidence extracted from the most recent scientific articles, medical journals, books and patent records. Artificial intelligence technology helps scientists identify relationships between genes, proteins and drugs related to the diseases under study, streamlining the process of new scientific discoveries.
“With the integration of Watson into our RD&I team, through its Cognitive Intelligence, we will be able to evaluate thousands of documents and literature in a time interval that would be impossible in traditional means, as well as generate new research hypotheses with great capacity. preditiv”, evaluates TheraSkin Research, Development and Innovation manager, Deli Oliveira.
Brazil has a very timely and challenging scenario in terms of innovation in skin care products, especially because of the great mix of ethnicities present in the country and also because of its tropical profile. “In just 2 months of using Watson for Drug Discovery, we have already shown that it brings together a large amount of knowledge that can be absorbed in the form of new ideas to overcome these challenges. Our intention is also to support many projects that are in their initial phase, consolidate others in progress and make possible differentiated and agile paths in the development of products far from the obvious, something that in Research can be a great business opportunity for companies” , completes Oliveira.
The Watson for Drug Discovery platform is part of the services portfolio of the IBM Watson Health global business unit, which was launched in April 2015, and has the proposal to improve patient care through projects with cognitive computing. “In the health area, cognitive computing supports professionals – whether doctors, scientists or companies – so that their decisions are increasingly based on scientific data and, ultimately, more accurate”, emphasizes the leader of the IBM Watson Health unit in the Brazil, Eduardo Cipriani.
EN 
PT 
